AB0402 HIGHER LEVELS OF HIGH-SENSITIVITY CRP IS ASSOCIATED WITH FUTURE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PSORIASIS: A PROSPECTIVE COHORT STUDY

Background: Simple and accessible biomarkers that predict the development of psoriatic arthritis (PsA) among psoriasis patients are critically needed to improve early detection of high-risk individuals. High-sensitivity C-Reactive Protein (hs-CRP) is a biomarker of systemic inflammation. Objectives: We aimed to assess whether higher levels of hs-CRP are associated with risk of future development of PsA among patients with psoriasis. Methods: We analyzed data from a prospective cohort of patients with psoriasis without PsA at enrollment. Participants were assessed annually by a rheumatologist for signs and symptoms of PsA. Information on patient demographics, psoriasis features, medications and musculoskeletal symptoms was collected using standard protocols. hs-CRP levels were measured in serum samples collected at baseline using standard commercial assays in a hospital laboratory. The differences in average hs-CRP levels were assessed across pre-defined patient groups using t-test. The association between hs-CRP levels and risk of development of PsA was assessed using multivariable Cox proportional hazards model adjusted for age, sex, psoriasis duration, PASI, nail lesions, BMI, FACIT-fatigue, use of biologics, use of systemic non-biologics/phototherapy. Results: A total of 589 patients with psoriasis followed from 2006 to 2019 were analyzed. Mean duration of follow up was 7.5 years. 57 patients developed PsA during the follow up period (incidence of 1.2 events per year). The mean age of study participants was 47.3±13.5 (43.1% females), duration of psoriasis 16.2±14.4. Mean level of hsCRP was 3.1±5.5 mg/L (hsCRP levels in incident PsA cases: 5.4±13.1). Significantly higher levels of hs-CRP at baseline were found in patients with arthralgia (4.2±8.53 vs. 2.71±3.67 mg/L), obesity (4.75±4.95 vs. 2.45±5.61 mg/L) and in females (3.92±7.13 vs. 2.51±3.68 mg/L); see Table 1 . Higher hs-CRP levels were associated with future development of PsA in univariate analysis (hazard ratio (HR) 1.03, 95% Confidence Interval (CI) 1.01, 1.05, p=0.002). This association remained significant in the multivariable regression analysis (HR 1.04, 95% CI 1.01, 1.06, p=0.008). Similar effect size was seen in males and females ( Figure 1 ). No significant interaction was found between hs-CRP and sex or BMI. Conclusion: Higher levels of systemic inflammation, as measured by hs-CRP, identifies patients with psoriasis at high risk of future development of PsA. Acknowledgements: NIL. Disclosure of Interests: Lihi Eder Abbvie, BMS, Janssen, Eli Lilly, Novartis, UCB, Amgen, Novartis, Fresenius Kabi, Janssen, Pfizer, Eli Lilly, UCB, Sandoz, Vinod Chandran Abbvie, Amgen, BMS, Eli Lilly, Janssen, Novartis, UCB, Abbvie, Amgen, Eli Lilly, Cheryl F. Rosen Abbvie, Amgen, BMS, Eli Lilly, Novartis, UCB, Richard Cook: None declared, Dafna D. Gladman Abbvie, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer, UCB, Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB. Download: Download high-res image (150KB) Download: Download full-size image Download: Download high-res image (207KB) Download: Download full-size image

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.